Health
Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial
Headline as filed by Medical Xpress.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Medical Xpress | Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial |
In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune over |
0m | medicalxpress.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.